Why the study?
Does plasmapheresis reduce the serum activity level of dalteparin in a patient with pulmonary embolus?
Does plasmapheresis reduce the serum activity level of dalteparin in a patient with pulmonary embolus?
Plasmapheresis appears to significantly reduce the level of anticoagulation of dalteparin as measured by anti-Xa assay.
Answers are grounded in this paper and cite their sources.
Plasmapheresis may substantially reduce dalteparin anti-Xa activity in PE; leaves open whether dosing adjustments or alternatives are needed.
The effect of plasmapheresis on the anticoagulant properties of the low molecular weight heparins has never been studied. We had the opportunity to study this effect in a woman who was receiving dalteparin for the treatment of a pulmonary embolus and required plasmapheresis. Over the course of 8 days, five courses of plasmapheresis were performed. Anti-Xa activity was measured pre- and post-dalteparin administration both during and between the first three courses of plasmapheresis. Comparing the rate of change between pairs of anti-Xa activity, the absorption rate was found to have decreased by over 50%. The decay rate, as compared with a historical control, was found to have increased by over 480%. These results suggest that the level of anticoagulation of dalteparin, as monitored through an anti-Xa assay, is reduced by plasmapheresis.
No takes yet. Share an insight, caveat, or question.
Sabloff et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: